Another study showed that patients with a low T790M relative allele frequency (RAF) in their plasma (<20%), which was calculated as the ratio of the allele frequency (AF) of T790M to the AF of sensitizing mutations, had lower ORR (0 vs. 68.8%; p = 0.03) and DCR (60% vs. 100%; p = 0.048) values when treated with osimertinib compared to patients with a high T790M RAF, suggesting that non-response to osimertinib could be due to alternative resistance mechanisms to T790M, such as MET or ERBB2 amplification and SCLC transformation. Here, MET is linked to small cell lung carcinoma.